Literature DB >> 23105406

Reversible suppression of nitric oxide system in essential hypertension.

M Chandra1, D R Maurya, S Kumar, H Basara, A Ghatak, B L Tekwani, G Kaur, M K Misra.   

Abstract

Despite enormous research in the field of hypertension, its pathophysiology still remains largely unresolved and appears to be multifactorial. In the present communication, we have analyzed the status of nitric oxide (NO) in the patients with essential hypertension and age matched controls. We have found that the levels of NO are lowered in essential hypertension. The normalization of blood pressure by administration of antihypertensive therapy causes rise in the NO level indicating that perturbed NO status in essential hypertension is reversible. Addition of antioxidant to the antihypertensive drugs causes a further, though non significant, rise in the levels of NO, suggesting that antioxidants may be combined with antihypertensive drugs as adjunct in the management of essential hypertension.

Entities:  

Keywords:  Antihypertensive treatment; Antioxidants; Essential hypertension; Nitric oxide

Year:  2003        PMID: 23105406      PMCID: PMC3453892          DOI: 10.1007/BF02867381

Source DB:  PubMed          Journal:  Indian J Clin Biochem        ISSN: 0970-1915


  19 in total

1.  Basal nitric oxide synthesis in essential hypertension.

Authors:  P Forte; M Copland; L M Smith; E Milne; J Sutherland; N Benjamin
Journal:  Lancet       Date:  1997-03-22       Impact factor: 79.321

2.  Hypertension in mice lacking the gene for endothelial nitric oxide synthase.

Authors:  P L Huang; Z Huang; H Mashimo; K D Bloch; M A Moskowitz; J A Bevan; M C Fishman
Journal:  Nature       Date:  1995-09-21       Impact factor: 49.962

3.  Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension.

Authors:  J A Panza; A A Quyyumi; J E Brush; S E Epstein
Journal:  N Engl J Med       Date:  1990-07-05       Impact factor: 91.245

4.  Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo. Blunted response in essential hypertension.

Authors:  L Linder; W Kiowski; F R Bühler; T F Lüscher
Journal:  Circulation       Date:  1990-06       Impact factor: 29.690

Review 5.  Nitric oxide: a physiologic messenger.

Authors:  C J Lowenstein; J L Dinerman; S H Snyder
Journal:  Ann Intern Med       Date:  1994-02-01       Impact factor: 25.391

6.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.

Authors:  R F Furchgott; J V Zawadzki
Journal:  Nature       Date:  1980-11-27       Impact factor: 49.962

7.  Are free radicals involved in the pathobiology of human essential hypertension?

Authors:  K V Kumar; U N Das
Journal:  Free Radic Res Commun       Date:  1993

8.  Effect of salt intake and inhibitor dose on arterial hypertension and renal injury induced by chronic nitric oxide blockade.

Authors:  S S Yamada; A L Sassaki; C K Fujihara; D M Malheiros; G De Nucci; R Zatz
Journal:  Hypertension       Date:  1996-05       Impact factor: 10.190

Review 9.  Nitric oxide: mediator, murderer, and medicine.

Authors:  E Anggård
Journal:  Lancet       Date:  1994-05-14       Impact factor: 79.321

10.  Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension.

Authors:  A Bonnardeaux; S Nadaud; A Charru; X Jeunemaitre; P Corvol; F Soubrier
Journal:  Circulation       Date:  1995-01-01       Impact factor: 29.690

View more
  2 in total

1.  Effect of vitamin E administration on blood pressure following reperfusion of patients with myocardial infarction.

Authors:  Rashmi Raghuvanshi; Mahesh Chandra; Aparna Mishra; Mithilesh K Misra
Journal:  Exp Clin Cardiol       Date:  2007

2.  Hyperglycaemia enhances nitric oxide production in diabetes: a study from South Indian patients.

Authors:  Ramu Adela; Susheel Kumar Nethi; Pankaj K Bagul; Ayan K Barui; Saidulu Mattapally; Madhusudan Kuncha; Chitta R Patra; P Naveen Chander Reddy; Sanjay K Banerjee
Journal:  PLoS One       Date:  2015-04-20       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.